MedTrace Logo

Aimovig Pregnancy Exposure Registry

NCT06150781 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2842

Last updated 2025-11-04

No results posted yet for this study

Summary

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.

Conditions

Interventions

DRUG

erenumab-aooe

Dose and treatment duration will be advised by the HCP

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-27
Primary Completion
2027-10-28
Completion
2027-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150781 on ClinicalTrials.gov